.png){kind=icon}
.png){kind=icon}
Return
Oxeiptosis – potential in cancer treatment?
.png){kind=icon}
OA
AI
M
K
Ż
R
DOI：10.1017/erm.2026.10045.png)
.png){kind=icon}
Original request for help.png){kind=icon}
Share.png){kind=icon}
Save
Abstract
En 中文
Oxeiptosis is a reactive oxygen species (ROS)-dependent form of programmed cell death that plays a key role in cellular homeostasis and holds promise as a cancer therapy. This review explores its molecular mechanisms; emphasizing the KEAP1–PGAM5–AIFM1 signalling pathway and its reliance on ROS accumulation. Compared to other cell death pathways; oxeiptosis offers a distinct approach; especially for targeting cancer cells resistant to conventional therapies. The review evaluates emerging inducers; both synthetic and natural; that selectively trigger oxeiptosis in cancer cells. It also examines the potential synergy between oxeiptosis and ROS-generating chemotherapies; particularly in the oxidative tumour microenvironment. However; challenges remain; including identifying tumour-specific inducers; overcoming cancer cell resistance to oxidative stress and reducing off-target effects. The review concludes by highlighting the need for targeted delivery strategies and rigorous preclinical studies to translate oxeiptosis into effective cancer treatments. Overall; it underscores oxeiptosis as a promising avenue to address drug resistance and improve therapeutic outcomes in oncology.
Keywords:
cell death
chemotherapy
oxeiptosis
oxidative stress
reactive oxygen species (ROS)
Journal
IF:
5.5
Papers:
76
Citations:
2.2K
Organization
Cited Papers